FOLFOXIRI plus bevacizumab

DRUG2 trials

Sponsors

Azienda Ospedaliero, Universitaria Pisana

Conditions

Metastatic Colorectal CancerRectal Cancer

Phase 2

Folfoxiri Plus Bevacizumab Followed by Chemoradiotherapy Plus Bevacizumab in Patients With Resectable Rectal Cancer

CompletedNCT03085992

Azienda Ospedaliero, Universitaria PisanaRectal Cancer

Start: 2012-03-31End: 2018-03-12Updated: 2018-03-14

Unknown Phase

First-line FOLFOXIRI Plus Bevacizumab in BRAF Mutant Metastatic Colorectal Cancer

CompletedNCT01437618

Azienda Ospedaliero, Universitaria PisanaMetastatic Colorectal Cancer

Start: 2009-06-30End: 2011-05-31Updated: 2011-09-21

Related Papers

FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.

2013-10-15141 citations